Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5663581 | Acta Haematologica Polonica | 2017 | 7 Pages |
Abstract
Rituximab is a milestone in treatment of many hematological and autoimmune diseases. Considering how widespread has the use of rituximab become, the overall risk of developing PML is relatively low. Nevertheless, since the end of 1990s several reports were published on PML development in association with usage of rituximab. The authors would like to emphasize that although the total risk of PML occurrence in patients treated with rituximab is low, it is important that physicians administrating rituximab therapy are aware of this serious complication.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Moa Forssberg, Monika Klimkowska, Maciej Machaczka,